TY - JOUR
T1 - Clopidogrel use in children
AU - Finkelstein, Yaron
AU - Nurmohamed, Laila
AU - Avner, Marina
AU - Benson, Lee N.
AU - Koren, Gideon
N1 - Funding Information:
Finkelstein is supported by a fellowship grant from The Hospital for Sick Children Research Training Center. Koren is a Senior Scientist of the Canadian Institute for Health Research and holder of the Ivey Chair in Molecular Toxicology, University of Western Ontario, London, Ontario.
PY - 2005/11
Y1 - 2005/11
N2 - Objectives: To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen. Study design: A retrospective chart review of all infants and children treated with clopidogrel at The Hospital for Sick Children, Toronto between January 2001 and April 2004. Clopidogrel dosages, duration of therapy, complications, and adverse effects in a pediatric population were explored. Results: Fifteen infants and children with congenital and acquired heart disease were treated with clopidogrel (median age, 3.5 years; range, 6 weeks to 16 years). Dosages ranged from 1 to 6 mg/kg/day for periods between 1 month and 6 months. Although no thrombotic events were reported, 1 child had a bleeding complication (gastrointestinal) while on triple antithrombotic therapy. Other complications reported in adults, including rash and clinical thrombocytopenia, were not noted in this pediatric series. Conclusions: Clopidogrel was well tolerated. We suggest a starting dose of 1 mg/kg/day for children.
AB - Objectives: To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen. Study design: A retrospective chart review of all infants and children treated with clopidogrel at The Hospital for Sick Children, Toronto between January 2001 and April 2004. Clopidogrel dosages, duration of therapy, complications, and adverse effects in a pediatric population were explored. Results: Fifteen infants and children with congenital and acquired heart disease were treated with clopidogrel (median age, 3.5 years; range, 6 weeks to 16 years). Dosages ranged from 1 to 6 mg/kg/day for periods between 1 month and 6 months. Although no thrombotic events were reported, 1 child had a bleeding complication (gastrointestinal) while on triple antithrombotic therapy. Other complications reported in adults, including rash and clinical thrombocytopenia, were not noted in this pediatric series. Conclusions: Clopidogrel was well tolerated. We suggest a starting dose of 1 mg/kg/day for children.
UR - http://www.scopus.com/inward/record.url?scp=27744583103&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2005.05.006
DO - 10.1016/j.jpeds.2005.05.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:27744583103
SN - 0022-3476
VL - 147
SP - 657
EP - 661
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 5
ER -